Novel Drug Targets for the Bradyzoite Form of Toxoplasma gondii.

IF 3.1 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
Research and Reports in Tropical Medicine Pub Date : 2025-03-29 eCollection Date: 2025-01-01 DOI:10.2147/RRTM.S431290
Justin Orlando Ortiz, Anna K Potter, Imaan Benmerzouga
{"title":"Novel Drug Targets for the Bradyzoite Form of <i>Toxoplasma gondii</i>.","authors":"Justin Orlando Ortiz, Anna K Potter, Imaan Benmerzouga","doi":"10.2147/RRTM.S431290","DOIUrl":null,"url":null,"abstract":"<p><p><i>Toxoplasma gondii</i> is a world-wide parasite, with an estimated prevalence of approximately 30%. Toxoplasmosis is a severe disease in the immunocompromised, but few symptoms are exhibited by patients with an intact immune system, making this parasite a worldwide burden. Currently, few drugs exist in treating acute toxoplasmosis and no drugs exist to eliminate the bradyzoite of <i>T. gondii</i>. Effective therapies against acute and chronic toxoplasmosis are urgently needed to reduce the burden of this disease. This review aims to give a summary of recent findings in the bradyzoite form of <i>Toxoplasma gondii</i> and the implication of these findings on drug development. A thorough search of PubMed and Google Scholar databases was used to identify studies within the past 10 years that illustrate targetable key elements in the differentiation and formation of the bradyzoite form of <i>T. gondii.</i></p>","PeriodicalId":21138,"journal":{"name":"Research and Reports in Tropical Medicine","volume":"16 ","pages":"25-30"},"PeriodicalIF":3.1000,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11963886/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research and Reports in Tropical Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/RRTM.S431290","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Toxoplasma gondii is a world-wide parasite, with an estimated prevalence of approximately 30%. Toxoplasmosis is a severe disease in the immunocompromised, but few symptoms are exhibited by patients with an intact immune system, making this parasite a worldwide burden. Currently, few drugs exist in treating acute toxoplasmosis and no drugs exist to eliminate the bradyzoite of T. gondii. Effective therapies against acute and chronic toxoplasmosis are urgently needed to reduce the burden of this disease. This review aims to give a summary of recent findings in the bradyzoite form of Toxoplasma gondii and the implication of these findings on drug development. A thorough search of PubMed and Google Scholar databases was used to identify studies within the past 10 years that illustrate targetable key elements in the differentiation and formation of the bradyzoite form of T. gondii.

弓形虫是一种全球性寄生虫,估计发病率约为 30%。弓形虫病对免疫力低下的人来说是一种严重的疾病,但免疫系统完好的病人却很少出现症状,因此这种寄生虫成为全世界的负担。目前,治疗急性弓形虫病的药物很少,也没有消除刚地弓形虫缓虫的药物。目前迫切需要针对急性和慢性弓形虫病的有效疗法,以减轻这种疾病的负担。这篇综述旨在概述最近在刚地弓形虫的裂殖体形式方面的发现,以及这些发现对药物开发的影响。我们对 PubMed 和 Google Scholar 数据库进行了全面搜索,以确定过去 10 年中有哪些研究说明了刚地弓形虫幼虫形态分化和形成过程中的可靶向关键因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Research and Reports in Tropical Medicine
Research and Reports in Tropical Medicine MEDICINE, RESEARCH & EXPERIMENTAL-
自引率
0.00%
发文量
7
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信